Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
TAPAS TRIAL |
|
|---|---|
| Problem | STEMI |
| Format | Single-center, prospective, randomized, open trial involving the blinded evaluation of end points |
| Treatment | Thrombus aspiration |
| Control | Conventional PCI |
| Population | 1071 patients |
| Inclusion criteria | Symptoms suggesting acute myocardial ischemia lasting more than 30 minutes The onset of symptoms less than 12 hours previously ST-segment elevation of more than 0.1 mV in two or more leads on the ECG |
| Exclusion criteria | Performance of a rescue PCI after thrombolysis Known existence of a disease resulting in a life expectancy of less than 6 months Lack of informed consent. |
| Follow-up | 30 days |
| Primary endpoint | Postprocedural frequency of a myocardial blush grade of 0 or 1 |
| Secondary endpoint(s) | Postprocedural frequencies of a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 3 Complete resolution of ST-segment elevation The absence of persistent ST-segment deviation Rarget-vessel revascularization Reinfarction Death Combination of major adverse cardiac events |
| Details | - |
| Brief summary: | Thrombus aspiration during PCI for STEMI improves mortality |
| PAPER: Thrombus aspiration during primary percutaneous coronary intervention. | |
|---|---|
| Date | 7 Feb 2008 |
| Journal | N Engl J Med. 2008 Feb 7;358(6):557-67. |
| Information | Thrombus aspiration in STEMI assoc. with: -Improved blush grade on post-PCI angio (P<0.001) -Improved resolution of ST-segment elevation (P<0.001) -Improved mortality @ 30d (P=0.003) -Lower adverse events (P<0.001) All irrespective of baseline clinical/angio characteristics N.B. Single centre |
| PAPER: Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study | |
|---|---|
| Date | 7 Jun 2008 |
| Journal | Lancet. 2008 Jun 7;371(9628):1915-20. |
| Information | Thrombus aspiration for STEMI @ 1 year -Improved cardiac mortality (3.6% vs. 6.7%; p=0.020) -Improved cardiac mortality and non-fatal reinfarction (5.6% vs. 9.9%; p=0.009) |